Sponsor content
56 result(s) found, displaying 1 to 10
- Australian Public Assessment Report (AusPAR)AusPAR: ApretudeAusPAR for Apretude (cabotegravir) for the prevention (to reduce the risk) of sexually acquired HIV-1 infection.
- ARTGAPRETUDE cabotegravir (as sodium) 30 mg film coated tablet bottle (377442)Australian Register of Therapeutic Goods (ARTG) information for APRETUDE cabotegravir (as sodium) 30 mg film coated tablet bottle.
- ARTGAPRETUDE cabotegravir 600 mg/3 mL prolonged-release suspension for injection vial (377474)Australian Register of Therapeutic Goods (ARTG) information for APRETUDE cabotegravir 600 mg/3 mL prolonged-release suspension for injection vial.
- Prescription medicine registrationAPRETUDE (ViiV Healthcare Pty Ltd)Active ingredients: cabotegravir sodium, cabotegravir.
- Australian Public Assessment Report (AusPAR)AusPAR: Tivicay and Tivicay PDTIVICAY (dolutegravir ) for treatment of HIV infection in combination with other antiretroviral agents.
- Australian Public Assessment Report (AusPAR)AusPAR: Fostemsavir trometamolAustralian Public Assessment Report for Fostemsavir trometamol
- ARTGTIVICAY PD dolutegravir (as sodium) 5 mg dispersible tablet bottle (340591)Australian Register of Therapeutic Goods (ARTG) information for TIVICAY PD dolutegravir (as sodium) 5 mg dispersible tablet bottle.
- Prescription medicine registrationTIVICAY and TIVICAY PD (ViiV Healthcare Pty Ltd)Active ingredients: dolutegravir and dolutegravir (as sodium).
- Prescription medicine registrationTIVICAY and TIVICAY PD (ViiV Healthcare Pty Ltd)Active ingredients: dolutegravir and dolutegravir (as sodium).
- Designation or determinationNotice for cabotegravir (as sodium) and cabotegravir (ViiV Healthcare Pty Ltd)Priority review